227 related articles for article (PubMed ID: 20538658)
1. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Takahashi K; Nishimura T
Br J Ophthalmol; 2010 Sep; 94(9):1215-8. PubMed ID: 20538658
[TBL] [Abstract][Full Text] [Related]
2. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
[TBL] [Abstract][Full Text] [Related]
3. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
[TBL] [Abstract][Full Text] [Related]
4. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.
Matsuyama K; Ogata N; Jo N; Shima C; Matsuoka M; Matsumura M
Jpn J Ophthalmol; 2009 May; 53(3):243-8. PubMed ID: 19484443
[TBL] [Abstract][Full Text] [Related]
5. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
[TBL] [Abstract][Full Text] [Related]
6. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
8. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
9. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
Mohan N; Monickaraj F; Balasubramanyam M; Rema M; Mohan V
J Diabetes Complications; 2012; 26(5):435-41. PubMed ID: 22699109
[TBL] [Abstract][Full Text] [Related]
10. Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes.
Nam DH; Oh J; Roh JH; Huh K
Ophthalmologica; 2009; 223(3):188-91. PubMed ID: 19182495
[TBL] [Abstract][Full Text] [Related]
11. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
[TBL] [Abstract][Full Text] [Related]
12. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy.
Ogata N; Matsuoka M; Matsuyama K; Shima C; Tajika A; Nishiyama T; Wada M; Jo N; Higuchi A; Minamino K; Matsunaga H; Takeda T; Matsumura M
J Clin Endocrinol Metab; 2007 Mar; 92(3):1176-9. PubMed ID: 17213275
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion.
Drechsler F; Köferl P; Hollborn M; Wiedemann P; Bringmann A; Kohen L; Rehak M
Ophthalmic Res; 2012; 47(3):157-62. PubMed ID: 22116547
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
[TBL] [Abstract][Full Text] [Related]
16. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
Costagliola C; Semeraro F; dell'Omo R; Romano MR; Russo A; Aceto F; Mastropasqua R; Porcellini A
Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
[TBL] [Abstract][Full Text] [Related]
18. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
[TBL] [Abstract][Full Text] [Related]
19. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
